Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis - PubMed
3 hours ago
- #Lipoprotein(a)
- #Inflammation
- #Coronary Artery Disease
- Elevated lipoprotein(a) [Lp(a)] levels show clinical heterogeneity, with prior studies suggesting low-grade inflammation may modify associated risks.
- This study tested if inflammatory biomarkers (IL-1β, IL-18, IL-6, NLR) modify Lp(a)-associated risk for coronary artery disease (CAD) and aortic valve stenosis (AS) in a primary prevention cohort.
- Among 43,512 UK Biobank participants, IL-6 demonstrated the strongest association with incident CAD and AS, significantly modifying Lp(a)-associated CAD risk.
- Higher IL-6 levels increased Lp(a)-associated CAD risk (HR 1.43 in highest IL-6 quartile vs. 1.09 in lowest), with a significant interaction (P = .008).
- No inflammatory biomarkers modified Lp(a)-associated risk for AS, and the NLR interaction was suggestive but not significant after multiple testing adjustments.
- Findings identify IL-6 as a key inflammatory biomarker that may modify Lp(a)-associated CAD risk, highlighting potential for targeted risk stratification.